ArticleNPJ Parkinson's disease2025
Motor cortex stimulation ameliorates parkinsonian locomotor deficits: effectual and mechanistic differences from subthalamic modulation.
Article in NPJ Parkinson's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Quantifying spike train synchrony and directionality: Measures and Applications.Biological cybernetics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Subthalamic deep brain stimulation (STN DBS) has been a therapeutic choice for Parkinson's disease (PD). We found that epidural motor cortex stimulation (MCS) with sustained positive (hyperpolarizing) currents could also consistently ameliorate the locomotor deficits in parkinsonian animals, rectifying the pathological paucity in both discharging unit varieties and movement-dependent spatiotemporal activity pattern changes in motor cortex (MC). Mechanistically, MCS hyperpolarizes both glutamatergic pyramidal neurons (PN) and GABAergic interneurons (IN) and consequently partly relieves PN from IN's control. MC discharging units are thus enlarged with enhanced PN burst discharges against a relatively silenced background, presumably compensating for the hypoactive striatal selection to restore the MC activity changes upon movement. Behaviorally, MCS retains interim short pauses like normal locomotor behaviors, in contrast to the propensity of abnormal "restlessness" with STN DBS. Individually designed MCS, alone or in combination with STN DBS and dopaminergic therapy, may provide an optimal therapeutic approach for PD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.